ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery
SOLANA BEACH, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has entered into a multi-year license agreement with UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical leader, to partner on drug delivery platforms for UCB’s gene therapy portfolio.
“We are extremely excited to partner with UCB, a global biopharmaceutical leader, with a focus on innovating through the adoption of next generation science and new technologies,” stated Jeremy Stigall, Executive Vice President and General Manager of Biologics and Drug Delivery at ClearPoint Neuro. “Over the past year, we have invested heavily in expanding our Biologics and Drug Delivery team, as well as our product and services portfolio to attract partners of UCB’s caliber. UCB sought comprehensive tools to empower a seamless transition from benchtop testing to commercial success, and that’s precisely what our team can deliver today.”
Under the terms of the license agreement, UCB will utilize ClearPoint Neuro’s proprietary technology and services in connection with the development and commercialization of UCB’s gene therapy products. ClearPoint Neuro will receive success-based milestone payments. Further financial details of the agreement were not disclosed.
Dhaval Patel, Executive Vice President and UCB’s Chief Scientific Officer, said, “We look forward to the ClearPoint Neuro collaboration as we work on advancing UCB’s research and development pipeline in gene therapy. We believe that ClearPoint Neuro are a strong strategic fit for UCB as they are a company dedicated to innovation in the neurology space with a unique portfolio of navigation and drug delivery tools.”
About ClearPoint Neuro
ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 65 active sites in North America, Europe, and South America. ClearPoint Neuro is partnered with more than 50 pharmaceutical/biotech companies, academic centers, and contract research organizations providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 6,000 procedures have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.
Statements in this press release and in the teleconference referenced above concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, the size of total addressable markets or the market opportunity for the Company’s products and services, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of the COVID-19 pandemic, global instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company’s ClearPoint Neuro Navigation System and other new products offered by the Company; the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System and other new products offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of our products and services in their delivery of therapies; and risks inherent in the research and development of new products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, which has been filed with the Securities and Exchange Commission, and the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2023, which the Company filed with the Securities and Exchange Commission on May 15, 2023.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
AccuStem Sciences, Inc. Announces Collaboration Agreement with University Hospitals6.6.2023 07:00:00 CEST | Press release
LONDON and PHOENIX, Ariz., June 06, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today announced the establishment of a joint clinical collaboration agreement with University Hospitals. Per the terms of this agreement, University Hospitals will provide tissue samples with clinical outcomes to AccuStem for research purposes. The scope of the agreement covers a multitude of different cancers but will initially focus on breast cancer cases to support further validation of the StemPrintER test. The goal of the initial project is to build on the strong foundation of data for StemPrintER by demonstrating additional clinical utility beyond identifying patients’ risk of recurrence. This next step is critical for women with early stage breast cancer because there are many tests to determine the need for chemotherapy but there are no genomic tools to inform decisions earlier in the c
TGS Expands Multi-Client Coverage for Malvinas 3D Offshore Argentina6.6.2023 07:00:00 CEST | Press release
OSLO, Norway (6 June 2023) – TGS, a leading global provider of energy data and intelligence, announced today Malvinas 3D Phase III, an expansion of its multi-client 3D coverage in Malvinas Basin offshore Argentina. The company plans to acquire a ~7,500 square kilometer 3D seismic survey and upon completion, TGS will have built a 3D library of 25,000 square kilometers in the Malvinas Basin. Kristian Johansen, TGS CEO, commented, "We are pleased to announce the expansion of our multi-client coverage for the Malvinas 3D project offshore Argentina. This project demonstrates our commitment to continuously providing our clients with the most up-to-date and accurate information to drive their exploration efforts. By leveraging our advanced seismic imaging technology, we aim to unlock the full potential of this region and support the energy industry in its pursuit of sustainable energy resources." Acquisition of Malvinas 3D Phase III is expected to commence by early 2024. This project is suppo
Santhera Publishes Agenda for its Annual General Meeting6.6.2023 07:00:00 CEST | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, June6, 2023 – Santhera Pharmaceuticals (SIX: SANN) today published the agenda for its Annual General Meeting (AGM), which will be held on June 27, 2023, at 10:00 CESTat Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Switzerland. The invitation to the Annual General Meeting with agenda items and explanations can be viewed on Santhera’s website at https://www.santhera.com/share-bondholder-meetings. Selected agenda items Elections The Board of Directors proposes the re-election of Thomas Meier, PhD, and Philipp Gutzwiller as members of the BoD until the end of the AGM 2024. Additionally, Thomas Meier, PhD, is nominated for re-election as the Chairman of the BoD. Patrick Vink, member of Santhera’s Board and Chairman of the Compensation Committee since 2017, decided not to stand for re-electi
Idorsia has entered into exclusive negotiations with regard to a prospective strategic transaction for its Asia Pacific (ex-China) operations for up to CHF 400 million6.6.2023 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June06, 2023 Idorsia Ltd (SIX: IDIA) today announced that it has entered into exclusive negotiations with an undisclosed party regarding its operating businesses in the Asia Pacific (ex-China) region, including selected license rights to products from Idorsia’s portfolio in those territories, for a total consideration of up to CHF 400 million. This prospective strategic transaction is subject to completion of satisfactory due diligence and legal documentation. Further announcements will be made as appropriate. André C. Muller, Chief Financial Officer of Idorsia, added: “This prospective strategic transaction would allow Idorsia to realize the significant value we have created in the region, and would extend our cash runway, while maintaining relationships for the future development and commercialization of our pipeline programs in the region. I would expect the potential transaction to be completed during July, subject
Ai-Media to Launch AI-Powered Automatic Captioning Solution to Asian Market at BroadcastAsia6.6.2023 06:00:00 CEST | Press release
SYDNEY, Australia, June 06, 2023 (GLOBE NEWSWIRE) -- Ai-Media, the leader in technology-driven live captioning, transcription, and translation solutions, is excited to announce its presence at BroadcastAsia in Singapore, where it will unveil its ground-breaking LEXI 3.0 automatic captioning solution to the Asian market. Previously launched to the North American market at NAB Show 2023, LEXI 3.0 is the new and improved version of Ai-Media’s flagship automatic captioning solution. Powered by AI, LEXI 3.0 is the world’s most accurate and advanced automatic captioning solution, delivering results that rival human captions at a fraction of the cost. During the BroadcastAsia, Ai-Media will also showcase its comprehensive range of captioning technology that boasts seamless integration with LEXI 3.0. Among the featured products is the new LEXI Viewer, an innovative HD-SDI device that empowers event organizers to effortlessly enhance accessibility by streaming captions to in-venue displays. Add